# Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

> **NCT00927472** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 254 (actual)

## Conditions studied

- Pediculosis

## Interventions

- **DRUG:** Malathion gel 0.5%
- **DRUG:** Permethrin 1% rinse

## Key facts

- **NCT ID:** NCT00927472
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2014-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927472, "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00927472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*